Genetec Corp.

As of March 31, 2026, Genetec Corp. carries a market capitalization of 5.47B, placing it among publicly traded companies globally. Its enterprise value stands at 5.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genetec Corp.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, Genetec Corp. has 11.57M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Genetec Corp. maintains a current ratio of 1.49, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Genetec Corp.'s stock has declined approximately 22.47% over the past 52 weeks. The 50-day moving average sits at 387.14, while the 200-day moving average is 429.19.

As of March 31, 2026, Genetec Corp. holds 1.60B in cash and equivalents against 2.07B in total debt, resulting in a net debt position of 464.70M. Total book value stands at 2.73B, with working capital of 1.47B providing operational flexibility.

Genetec Corp.'s most recent stock split took place on December 28, 2023 with a 1:3 split ratio.